Application of ACSS2 inhibitor in preparation of medicine for preventing and/or treating diabetic nephropathy
A technology for diabetic nephropathy and inhibitor, applied in the field of medicine, can solve the problem of not having both the effect of kidney protection, reducing the proteinuria of patients, podocyte damage, etc., and achieving the effect of reducing podocyte damage
Active Publication Date: 2019-10-15
SOUTHEAST UNIV
View PDF5 Cites 0 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
[0006] To sum up, the problems existing in the existing technology are: in some existing treatment techniques, the damage of podocytes caused by high glucose is relatively serious; in the clinical treatment of DN patients, while reducing the patient’s proteinuria, it is impossible to protect the kidneys at the same time. effect
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0032] Prevention and treatment of diabetic nephropathy: In this example, high glucose is used to stimulate podocytes to simulate the state of diabetes.
[0033] 1. Materials:
[0034] ACSS2 inhibitor was purchased from Shelleck Company; Trizol reagent was purchased from Life Technologies Company of the United States; 5×PrimeScript RT MasterMix was purchased from TaKaRa Company of Japan; Nanodrop 2000c excess microorganism detector was purchased from Thermo Scientific Company of the United States; PCR system 7300 was purchased from Applied Biosystems of the United States company; primers were synthesized by Nanjing Jierui Co., Ltd.
[0035] 2. Cell culture, grouping and processing:
[0036] Mouse podocytes were incubated with 1640 complete medium containing 10% BS, 100 U / ml penicillin and 100 μg / ml streptomycin at 37°C in a sterile incubator with 5% CO2. Podocytes with good growth and differentiation were selected and randomly divided into normal control group (equal volume ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The invention discloses an application of an ACSS2 inhibitor in preparation of a medicine for preventing and / or treating diabetic nephropathy. The invention finds that the ACSS2 inhibitor has remarkable effects in the aspect of preventing and / or treating the diabetic nephropathy, and can be applied to preparation of the medicine for preventing and / or treating the diabetic nephropathy, and ACSS2 serves as a new DN intervention target. According to the invention, the ACSS2 inhibitor is utilized to find that after the ACSS2 activity is inhibited, the podocyte damage caused by high glucose is reduced, which means that ACSS2 participates in the process of podocyte damage caused by high glucose and plays an important role. The ACSS2 inhibitor can inhibit important inflammatory factors IL-6, MCP-1 and TNF-alpha of diabetic nephropathy, transdifferentiation of diabetic nephropathy and expression of extracellular matrix-related proteins Collagen I and alpha-SMA, can promote the expression of the podocyte marker protein Nephrin, and has obvious effect of preventing and / or treating diabetic nephropathy.
Description
technical field [0001] The invention relates to the field of medicine, and relates to the application of an ACSS2 inhibitor in preparing a new target for diabetic nephropathy intervention, in particular to the application of an ACSS2 inhibitor in preventing and / or treating diabetic nephropathy. Background technique [0002] Diabetic nephropathy (DN) is the most common microvascular complication of diabetes mellitus (DM) and the leading cause of end-stage renal disease. The prevalence of diabetes among adults in my country is 11.6%, and the total number of patients is as high as 114 million, and nearly half of them will develop DN (Xu Y, et al. JAMA 2013; 310(9):948-959). The onset of DN is insidious, and the early diagnosis mainly depends on the measurement indicators such as urinary microalbumin excretion rate. When it is discovered, most of them have developed to stage III or above, and the disease continues to progress and is basically irreversible. Moreover, once diabet...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More IPC IPC(8): A61K31/498A61P3/10A61P13/12
CPCA61K31/498A61P3/10A61P13/12
Inventor 马坤岭鲁荐
Owner SOUTHEAST UNIV